Free same-day US shipping on orders over $150.00 · bulk pricing on 2+ vials
Kairo Labs
Shop
For research use only. Not for human or animal consumption.
Research Stack

The GLOW Stack: GHK-Cu, BPC-157 and TB-500 in Repair Research

The GLOW Stack is a co-formulated research reference that combines three structurally and mechanistically distinct peptides — GHK-Cu, a copper-binding tripeptide; BPC-157, an angiogenic pentadecapeptide; and TB-500, a thymosin β4 actin-binding fragment. These molecules are grouped not because they share a pathway but because they do not: the literature studies them across three non-overlapping axes of tissue-remodeling and repair biology in model systems. This reference explains the rationale for co-formulating them and summarizes what the peer-reviewed literature investigates for each, strictly for laboratory research use only — not for human or animal consumption.

The three-pathway rationale

The reason these three peptides appear together as the GLOW Stack is that each is characterized in the research literature through a different molecular mechanism. GHK-Cu is studied as a copper-peptide coordination complex acting on extracellular-matrix (ECM) and gene-expression endpoints; BPC-157 is studied for angiogenic and cytoprotective signaling associated with the VEGF and nitric-oxide systems; and TB-500 is studied through the thymosin β4 actin-binding system that governs cytoskeletal dynamics and cell migration. Three molecules, three distinct entry points into repair and remodeling biology.

This non-overlap is the entire point of the co-formulation. Rather than reinforcing a single pathway, the stack is assembled so that a researcher characterizing tissue-remodeling models can reference copper-peptide/ECM chemistry, angiogenic signaling, and actin-cytoskeletal dynamics from one place. The GLOW name is a product designation for the co-formulated reference material — it is not a description of any outcome, result, or effect in any organism.

  • GHK-Cu: copper-peptide / extracellular-matrix and gene-expression axis.
  • BPC-157: angiogenic and cytoprotective signaling axis (VEGF/NO-associated).
  • TB-500: actin-binding, cytoskeletal and cell-migration axis.
  • Co-formulated because the three pathways are distinct, not redundant.

GHK-Cu: copper-peptide biochemistry

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys), one of the most extensively studied copper-binding peptides in the biochemical literature. It is best characterized not as a free peptide but as a metal-peptide coordination complex: copper(II) is coordinated principally by the histidine imidazole nitrogen, the N-terminal glycine amino group, and the deprotonated amide nitrogen between glycine and histidine, forming a square-planar geometry stabilized by the lysine side chain. The apo-peptide has the formula C14H24N6O4 (~340.4 g/mol); the coordinated copper is what defines the complex's studied behavior.

In cell-culture and animal models the literature investigates GHK-Cu against extracellular-matrix endpoints — reported modulation of the expression of matrix components such as collagens and glycosaminoglycans, and of matrix-remodeling enzymes including matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) — alongside large-scale transcriptomic profiling that has reported broad gene-expression shifts. Because copper is a cofactor for matrix-crosslinking enzymes such as lysyl oxidase and redox enzymes such as superoxide dismutase, much of the proposed mechanism is reasoned in terms of copper coordination and exchange. This is mechanistic, model-level biochemistry — it is not, and is not presented as, a cosmetic, skincare, or anti-aging application in people.

  • Copper(II) complex of the tripeptide Gly-His-Lys, square-planar coordination.
  • Studied ECM endpoints: collagen and glycosaminoglycan expression in culture.
  • Matrix-remodeling enzymes (MMPs) and their inhibitors (TIMPs).
  • Copper as a cofactor for crosslinking and redox enzymes; broad transcriptomic modulation reported.

BPC-157: angiogenic mechanism

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain (sequence GEPPPGKPADDAGLV) — corresponding to a partial fragment of body protection compound, a protein originally identified in gastric juice. It is supplied as a fully synthetic peptide and is noted in the literature for unusual stability in aqueous and gastric-juice conditions relative to many peptides.

The research literature examines BPC-157 primarily in the context of angiogenesis — the formation of new blood vessels — in cellular and animal models. Studied mechanisms include modulation of angiogenic signaling associated with the vascular endothelial growth factor (VEGF) pathway and the nitric oxide (NO) system, along with interactions with growth-factor and cytoprotective signaling. Within the GLOW Stack, this angiogenic and cytoprotective axis is mechanistically separate from GHK-Cu's copper-peptide/ECM chemistry, which is why the two are co-studied rather than treated as interchangeable. These are preclinical and in-vitro findings describing the molecule's biology in models, not claims about any effect in humans.

  • 15-amino-acid pentadecapeptide, partial sequence of body protection compound.
  • Angiogenesis / new blood-vessel-formation signaling studied in models.
  • Associations with the VEGF pathway and the nitric oxide (NO) system.
  • Cytoprotective and growth-factor signaling investigated in vitro and in animals.

TB-500: actin and cytoskeletal mechanism

TB-500 is a synthetic peptide related to thymosin β4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein. Depending on the source, TB-500 is described either as full-length synthetic thymosin β4 or as a synthetic fragment centered on the molecule's key active region; the central, highly conserved actin-binding motif associated with the sequence is LKKTETQ. Because usage varies, the exact sequence in any given lot should be read from its Certificate of Analysis rather than assumed.

The defining, most-studied mechanism of thymosin β4 and its fragments is interaction with actin: the peptide binds monomeric G-actin and thereby helps regulate the balance between monomeric (G) and filamentous (F) actin, a balance central to the cytoskeletal dynamics that underlie cell migration and motility. In cellular and animal models the literature studies how this actin regulation relates to cell migration and repair-associated signaling, with associated effects on angiogenesis. This actin-cytoskeletal axis is the third distinct pathway in the GLOW Stack — mechanistically separate from both the copper-peptide/ECM chemistry of GHK-Cu and the angiogenic signaling of BPC-157.

  • Thymosin β4-related synthetic peptide; conserved actin-binding motif LKKTETQ.
  • Binds monomeric G-actin (actin sequestration).
  • Helps regulate the G-actin / F-actin balance underlying cell migration.
  • Cell-migration and angiogenesis-associated signaling studied preclinically.

Why three non-overlapping pathways, and lab handling

Grouping GHK-Cu, BPC-157 and TB-500 lets a researcher reference three complementary but independent axes of repair and remodeling biology from a single co-formulation: copper-peptide coordination and ECM/gene-expression chemistry, angiogenic and cytoprotective signaling, and actin-cytoskeletal dynamics. The value of the stack for research is precisely that the mechanisms do not overlap — each contributes a different molecular endpoint, so the three are studied as parallel inputs rather than one reinforced pathway.

As a co-formulated single-vial reference, the GLOW Stack is handled under standard lyophilized-peptide practice: the coordinated copper of GHK-Cu gives the material a characteristic blue coloration and introduces sensitivity to pH and to competing chelators in buffers, so diluent compatibility matters when the three components share one vial. Reconstitution follows the general laboratory reconstitution reference — gentle addition of an appropriate sterile diluent down the vial wall, dissolution by swirling or standing rather than vigorous agitation, and aliquoting to minimize freeze-thaw. Concentrations are defined by the researcher for the requirements of an assay, not by any dosing framework.

Every Kairo Labs lot is verified to the lot with a Certificate of Analysis documenting identity and purity by HPLC and mass spectrometry, so the composition of the co-formulation is characterized before research use. Nothing in this reference describes, recommends, or authorizes any human or animal use.

  • Three distinct axes: copper-peptide/ECM, angiogenic, actin-cytoskeletal.
  • Single-vial co-formulation; GHK-Cu's copper center adds pH/chelator sensitivity.
  • Reconstitution and storage per standard lyophilized-peptide laboratory practice.
  • Verified to the lot by HPLC and mass spectrometry; research use only.
Frequently asked
What is the GLOW Stack?

The GLOW Stack is a co-formulated research reference combining three distinct peptides: GHK-Cu (a copper-binding tripeptide studied on extracellular-matrix and gene-expression endpoints), BPC-157 (an angiogenic pentadecapeptide), and TB-500 (a thymosin β4 actin-binding fragment). GLOW is the product designation for the co-formulation, not a claim about any result. It is supplied for research use only.

Why are these three peptides studied together?

Because each is characterized through a different, non-overlapping mechanism: GHK-Cu through copper-peptide coordination and ECM/gene-expression chemistry, BPC-157 through angiogenic and cytoprotective signaling associated with the VEGF and nitric-oxide systems, and TB-500 through the thymosin β4 actin-binding system. The three represent parallel axes of tissue-remodeling and repair research in model systems rather than one reinforced pathway.

Is GHK-Cu in the GLOW Stack a skincare or cosmetic ingredient?

No. This reference frames GHK-Cu strictly as a copper-peptide coordination complex studied in the biochemical literature for extracellular-matrix, matrix-remodeling-enzyme (MMP/TIMP), and transcriptomic endpoints in model systems. It describes mechanistic, model-level research, not any cosmetic, skincare, or anti-aging application in people.

How is the GLOW Stack handled in the laboratory?

As a lyophilized single-vial co-formulation handled under standard peptide practice: gentle reconstitution with an appropriate sterile diluent, dissolution by swirling or standing rather than shaking, aliquoting to minimize freeze-thaw, and cold storage. GHK-Cu's coordinated copper adds sensitivity to pH and competing chelators, so diluent compatibility matters. Concentrations are set by the researcher for the assay, not by any dosing framework.

Is the GLOW Stack available for any human or animal use?

No. It is supplied strictly as a research reference material for research use only. It is not for human or animal consumption, and this page describes only the molecular rationale, mechanisms studied in models, and laboratory handling — no therapeutic claims, outcomes, or dosing.

Research Use Only. All products and information referenced by Kairo Labs are intended strictly for laboratory research and educational purposes. They are not for human or animal consumption, and not for diagnostic, therapeutic, or clinical use. This content describes mechanisms, molecular properties, and handling as studied in the scientific literature; it is educational, not medical advice, and not a recommendation to use any compound in humans or animals. Researchers are responsible for handling all materials in accordance with applicable laws, regulations, and institutional safety protocols.